Nephrotic syndrome with dense deposit disease in India: Symptoms, Causes & Treatment | aihealz
ICD variantNephrotic syndrome with dense deposit disease is a specific ICD-10 coded subtype of Nephrotic Syndrome. The clinical content below covers Nephrotic Syndrome in general.
UrologymoderateICD-10 · N04.6
Nephrotic syndrome with dense deposit disease.Care & specialists in India
In India, nephrotic syndrome with dense deposit disease is managed by urologists. Nephrotic syndrome is a clinical state defined by heavy urinary protein loss exceeding 3.5 g per 24 hours in adults (or urine protein/creatinine ratio above 2.0 mg/mg in children), serum albumin below 3.0 g/dL, peripheral edema, and hyperlipidemia. The underlying defect is increased glomerular permeability driven by podocyte injury, immune-complex deposition, or genetic protein mutation.
aliases · Nephrotic Syndrome (heavy protein leak kidney disease)· Nephrotic syndrome· Síndrome nefrótico· Sindrome nefrosica· reviewed May 14, 2026
EB
Reviewed by AIHealz Medical Editorial Board · UrologyLast reviewed May 13, 2026
Nephrotic syndrome (ICD-10: N04) is a glomerular disorder characterized by the triad of heavy proteinuria (>3.5 g/24 h in adults, urine protein/creatinine ratio >2.0 mg/mg in children), hypoalbuminemia (<3.0 g/dL), and peripheral edema, frequently accompanied by hyperlipidemia and a hypercoagulable state. The unifying pathophysiology is loss of the glomerular filtration barrier — specifically podocyte foot-process effacement and slit-diaphragm disruption — which allows albumin and other plasma proteins to spill into urine. In children, more than 85% of cases are minimal change disease, a podocytopathy responsive to corticosteroids. In adults, the spectrum is broader: primary glomerular diseases (membranous nephropathy, focal segmental glomerulosclerosis, minimal change disease, IgA-related variants) account for half of cases, while secondary causes (diabetes mellitus, systemic lupus erythematosus, amyloidosis, hepatitis B and C, HIV, malignancy, and certain drugs) explain the rest.
key facts
Prevalence
Annual incidence 2-7 per 100,000 children and approximately 3 per 100,000 adults in the United States and Europe
Demographics
Children: 60-70% are male; peak age 2-6 years. Adults: membranous nephropathy peaks at 50-60 years, FSGS at 30-50 years, with higher rates in Black populations (FSGS 3-5× higher than White)
Avg. age
Children: peak onset 2-6 years; adults: bimodal at 30-50 and 60-70 years
Global cases
Approximately 16 cases per 100,000 children worldwide carry chronic or relapsing disease; global adult prevalence not precisely measured but estimated at hundreds of thousands
§ 02
How you might notice it
The key symptoms of Nephrotic syndrome with dense deposit disease are: Bilateral lower-extremity pitting edema starting at the ankles, progressing to the calves, thighs, and abdominal wall, often worst at end of day and improved overnight., Periorbital puffiness on waking, frequently the earliest sign in children and mistaken for allergic conjunctivitis., Foamy or frothy urine that persists in the toilet bowl, reflecting heavy proteinuria., Rapid weight gain of 2-10 kg over days to weeks from fluid retention, with tightening of clothing and shoes., Generalized swelling (anasarca) with abdominal distension, scrotal or labial edema, and pleural effusions producing dyspnea in severe cases., Fatigue, malaise, reduced appetite, and easy bruising linked to protein loss, hypoalbuminemia, and altered coagulation., Decreased urine output and dark concentrated urine during marked fluid retention; conversely, polyuria from diuretic therapy once started..
01Bilateral lower-extremity pitting edema starting at the ankles, progressing to the calves, thighs, and abdominal wall, often worst at end of day and improved overnight.
02Periorbital puffiness on waking, frequently the earliest sign in children and mistaken for allergic conjunctivitis.
03Foamy or frothy urine that persists in the toilet bowl, reflecting heavy proteinuria.
04Rapid weight gain of 2-10 kg over days to weeks from fluid retention, with tightening of clothing and shoes.
§ 03
How it’s diagnosed
diagnosis
Initial evaluation confirms nephrotic-range proteinuria with a 24-hour urine collection or spot urine protein/creatinine ratio (>3.5 g/24 h or PCR >3.5 mg/mg in adults; >2.0 mg/mg in children), measures serum albumin (<3.0 g/dL confirms hypoalbuminemia), and assesses kidney function (creatinine, eGFR), lipid panel, urinalysis with microscopy (bland sediment supports primary nephrotic disease; red-cell casts shift toward a mixed nephritic-nephrotic picture), and serum complement (C3, C4). Secondary-cause screening is mandatory: HbA1c, hepatitis B surface antigen, hepatitis C antibody, HIV serology, antinuclear antibody, anti-dsDNA, complement, anti-PLA2R antibody (positive in 70-80% of primary membranous nephropathy), serum free light chains and immunofixation (amyloidosis), and age-appropriate cancer screening in adults over 50. In children with classic presentation (age 2-10, normal kidney function, no hematuria, complement normal), empiric corticosteroid therapy is started without biopsy because minimal change disease is overwhelmingly likely. In adults, atypical pediatric cases, and steroid-resistant disease, percutaneous kidney biopsy provides definitive light microscopy, immunofluorescence, and electron microscopy. Imaging (renal ultrasound, Doppler for renal-vein thrombosis) screens for anatomic causes and complications. KDIGO 2021 guideline frames diagnostic workflow.
Key tests
01
Urine protein/creatinine ratio (UPCR) on spot urineQuantifies proteinuria; UPCR >3.5 mg/mg confirms nephrotic range in adults
02
Serum albumin, creatinine, electrolytes, lipid panelConfirms hypoalbuminemia, assesses kidney function, identifies hyperlipidemia, and evaluates electrolyte derangements (hyponatremia, hypocalcemia from albumin loss)
03
Urinalysis with microscopyIdentifies hematuria, dysmorphic red cells, red-cell casts (nephritic features), and lipiduria (oval fat bodies, Maltese crosses)
§ 04
Treatment & cost
medical treatments
✓Prednisolone (60 mg/m²/day, max 60 mg, 4-6 weeks, then alternate-day taper) — pediatric minimal change disease
✓High-dose prednisone (1 mg/kg/day, max 80 mg, 12-16 weeks then taper) — adult primary FSGS or minimal change disease
✓Rituximab (1 g IV ×2, separated by 14 days, repeated at 6 months)
Kidney transplantation5-year graft survival 80-90% for living-donor and 70-80% for deceased-donor kidneys
Hemodialysis or peritoneal dialysis vascular/peritoneal access placementAVF primary patency 60-70% at 1 year; PD catheter survival 75-85% at 2 years
§ 05
Causes & risk factors
known causes
Minimal change disease (podocytopathy)
Idiopathic diffuse podocyte foot-process effacement, possibly driven by a circulating permeability factor and T-cell dysregulation. Causes more than 85% of pediatric and 10-15% of adult primary nephrotic syndrome. May follow viral illness or atopy.
Focal segmental glomerulosclerosis (primary, secondary, and genetic)
Primary FSGS is a podocytopathy with circulating permeability factor; secondary FSGS results from adaptive hyperfiltration in obesity, reflux nephropathy, solitary kidney, or after viral and drug exposure (HIV, pamidronate, anabolic steroids). Genetic FSGS arises from podocyte gene mutations (NPHS1, NPHS2, INF2, ACTN4).
Membranous nephropathy
Anti-PLA2R or anti-THSD7A antibodies bind antigens on podocyte foot processes, forming subepithelial immune-complex deposits that damage the glomerular basement membrane. Secondary forms accompany hepatitis B, lupus, malignancy (especially in patients over 65), and certain drugs.
Diabetic kidney disease
The leading cause of nephrotic-range proteinuria globally. Chronic hyperglycemia drives mesangial expansion, glomerular basement membrane thickening, podocyte loss, and nodular sclerosis. Onset typically 10-20 years into type 1 diabetes; earlier in type 2 with poor control or hypertension.
Systemic lupus erythematosus (class V membranous lupus)
Immune-complex deposition in the subepithelial space in 10-20% of patients with lupus nephritis. Anti-dsDNA antibodies, low complement, and other features of SLE help distinguish from primary membranous nephropathy.
Amyloidosis (AL or AA)
Deposition of misfolded immunoglobulin light chain (AL) or serum amyloid A (AA) protein in glomeruli. AL amyloidosis arises from a plasma cell dyscrasia; AA from chronic inflammation (rheumatoid arthritis, ankylosing spondylitis, familial Mediterranean fever, chronic infection).
§ 06
Living with it
01Maintain optimal glycemic control (HbA1c <7%) in diabetes to prevent diabetic kidney disease, the leading cause of nephrotic-range proteinuria globally.
02Treat hepatitis B and hepatitis C with effective antivirals to prevent virus-associated glomerular disease.
03Initiate antiretroviral therapy promptly in HIV infection to prevent HIV-associated nephropathy.
04Achieve blood pressure control below 130/80 mmHg with RAAS-blocking agents where feasible.
05Limit chronic NSAID use, particularly in patients with predisposing factors (older age, hypertension, prior kidney disease).
06Pneumococcal and influenza vaccination in patients with established proteinuria to reduce infection-triggered complications.
recommended foods
•Plant-forward diet rich in vegetables, fruits, legumes, and whole grains
•Adequate protein intake of 0.8-1.0 g/kg/day in non-CKD-progressing nephrotic syndrome; higher (1.0-1.2 g/kg/day) during relapse only under dietitian supervision
§ 07
When to seek help
why see an urology
All patients with nephrotic syndrome require nephrology evaluation. Specialist input is essential for biopsy decisions in adults, choice of immunosuppression, monitoring for treatment toxicity and thromboembolic complications, and recognition of secondary causes that require systemic therapy. Pediatric nephrology manages childhood-onset disease through induction, taper, and relapse.
01Venous thromboembolism, especially renal-vein thrombosis in membranous nephropathy (incidence 10-30%); prophylactic anticoagulation in high-risk patients reduces this.
02Infections (peritonitis, pneumonia, cellulitis), driven by hypogammaglobulinemia, immunosuppression, and edema-related skin breakdown; pneumococcal and influenza vaccination plus prompt treatment of febrile episodes.
03Acute kidney injury from intravascular depletion, NSAIDs, calcineurin inhibitor toxicity, or thrombotic occlusion.
04Hyperlipidemia and accelerated cardiovascular disease from chronic proteinuria.
05Corticosteroid toxicity (cushingoid features, hyperglycemia, osteoporosis, growth failure in children) — minimized by alternate-day dosing and steroid-sparing agents.
Minimal change disease (MCD)Diffuse podocyte foot-process effacement on electron microscopy with normal light microscopy. Accounts for >85% of pediatric and 10-15% of adult primary nephrotic syndrome. Responds to oral prednisolone in 80-90% within 4-8 weeks; relapsing forms managed with calcineurin inhibitors, mycophenolate, or rituximab.
Focal segmental glomerulosclerosis (FSGS)Segmental scarring in some glomeruli on light microscopy. Primary FSGS is a podocytopathy with circulating permeability factor; secondary FSGS results from hyperfiltration (obesity, reflux, single kidney) or viral, drug, or genetic causes. Black patients have 3-5× higher incidence linked to APOL1 risk variants. 30-50% progress to end-stage kidney disease without effective treatment.
Membranous nephropathy (MN)Subepithelial immune-complex deposits along the glomerular basement membrane. Most adult primary cases are PLA2R-antibody driven (70-80%). One-third remit spontaneously, one-third have persistent proteinuria, and one-third progress. Modern treatment is rituximab (MENTOR trial) or cyclophosphamide-steroid regimens.
Diabetic kidney disease (nodular glomerulosclerosis)Most common cause of nephrotic-range proteinuria in adults globally. Years of poorly controlled type 1 or type 2 diabetes produce Kimmelstiel-Wilson nodules, expanded mesangium, and progressive proteinuria. Managed with RAAS blockade, SGLT2 inhibitors, and glycemic control rather than immunosuppression.
Lupus nephritis class V (membranous lupus)Subepithelial immune-complex deposits resembling primary MN, occurring in 10-20% of lupus nephritis cases. Often presents with full nephrotic syndrome and is treated with mycophenolate or rituximab combined with steroids.
Amyloidosis (AL and AA)Extracellular deposition of misfolded protein in glomeruli. AL amyloidosis from plasma cell dyscrasia and AA amyloidosis from chronic inflammation present with nephrotic syndrome and require treatment of the underlying clonal or inflammatory disease.
Living with Nephrotic syndrome with dense deposit disease
Timeline
Children with minimal change disease typically remit within 2-4 weeks of starting prednisolone, with edema resolution and proteinuria clearance. Adult FSGS responses take 8-16 weeks of high-dose steroid therapy. Membranous nephropathy responds more slowly: rituximab effects on anti-PLA2R titres become apparent at 3-6 months and proteinuria clearance often takes 12-24 months. Maintenance immunosuppression and follow-up extend for years even after remission.
Lifestyle
01Restrict dietary sodium to under 2 g (87 mmol) per day to reduce edema and improve diuretic response.
02Weigh daily at the same time and record; report >2 kg gain in a week to the nephrology team.
03Adhere strictly to immunosuppression schedules and rituximab infusion appointments.
04Avoid NSAIDs unless explicitly approved by the nephrology team.
05Complete pneumococcal (PCV13 then PPSV23), influenza, hepatitis B, and varicella vaccinations before starting major immunosuppression.
06Stop smoking and limit alcohol to reduce cardiovascular and infection risk during prolonged proteinuria.
07Use compression stockings during prolonged immobility (long flights, post-operative) given thrombosis risk.
Daily management
Complementary approaches
Dietary salt restriction and weight monitoringSodium below 2 g per day reduces edema and supports diuretic action. Daily home weights flag fluid retention early.
Plasmapheresis for recurrent FSGS post-transplantRemoval of circulating permeability factor reduces proteinuria in recurrent FSGS after kidney transplantation; often combined with rituximab.
Choosing a doctor
Choose a nephrologist or pediatric nephrologist affiliated with a center that performs percutaneous kidney biopsy, has on-site renal pathology with immunofluorescence and electron microscopy, and a glomerular disease clinic familiar with rituximab, cyclophosphamide, and calcineurin inhibitor regimens. Centers participating in registries (NephCure, Cure GN) typically follow current KDIGO guidance.
Patient support resources
NephCure Kidney International →Patient advocacy organization focused on nephrotic syndrome, FSGS, and minimal change disease with educational resources and clinical trial directory.
Cure GN (CureGN consortium) →International registry and longitudinal cohort study for adults and children with primary glomerular disease.
§ 08
Frequently asked
What is nephrotic syndrome?▾▴
Nephrotic syndrome is a kidney disorder defined by heavy protein loss in urine (over 3.5 g/24 hours in adults), low serum albumin, peripheral edema, and high blood cholesterol. The underlying problem is a leaky glomerular filter, often from podocyte injury or immune-complex deposits.
What are the main symptoms of nephrotic syndrome?▾▴
The classic symptoms are foamy urine, swelling of the ankles, legs, and face (especially around the eyes on waking), rapid weight gain from fluid retention, fatigue, and reduced appetite. Severe cases develop generalized swelling (anasarca), shortness of breath, and abdominal distension.
What causes nephrotic syndrome in children?▾▴
More than 85% of childhood nephrotic syndrome is caused by minimal change disease, a podocyte injury that responds to corticosteroids in 80-90% of cases. Less common causes include focal segmental glomerulosclerosis (FSGS), membranous nephropathy, hereditary podocyte gene mutations, and infections.
What causes nephrotic syndrome in adults?▾▴
In adults, common causes include membranous nephropathy, focal segmental glomerulosclerosis (FSGS), minimal change disease, diabetic kidney disease, lupus nephritis, amyloidosis, and viral infections (HIV, hepatitis B and C). Diabetic kidney disease is the single most common cause globally.
How is nephrotic syndrome diagnosed?▾▴
Diagnosis is based on a 24-hour urine collection or spot urine protein/creatinine ratio above 3.5, serum albumin under 3.0 g/dL, and clinical edema. Adults usually require a kidney biopsy to identify the underlying cause. Blood tests screen for diabetes, lupus, viral infections, and PLA2R antibodies.
Is nephrotic syndrome curable?▾▴
Childhood minimal change disease has an excellent prognosis with 80-90% achieving complete remission with prednisolone, though relapses are common. Adult primary nephrotic syndromes such as FSGS and membranous nephropathy can achieve remission with immunosuppression in 50-65% of patients, with long-term kidney preservation strongly tied to response.
What is the first-line treatment for nephrotic syndrome?▾▴
First-line treatment depends on cause. Pediatric minimal change disease receives prednisolone 60 mg/m²/day. Adult primary membranous nephropathy now receives rituximab (MENTOR trial). FSGS receives high-dose prednisone. All patients receive ACE inhibitor or ARB, salt restriction, statin, and consideration of anticoagulation.
Why does nephrotic syndrome cause swelling?▾▴
Heavy urinary protein loss lowers blood albumin, reducing the oncotic pressure that holds fluid in blood vessels. Fluid leaks into tissues, producing pitting edema in the ankles, eyes, and abdomen. Sodium retention from activated renin-angiotensin and sympathetic systems further worsens fluid overload.
Can nephrotic syndrome cause blood clots?▾▴
Yes. Loss of antithrombin III and other coagulation regulators in urine, combined with increased clotting factor synthesis, makes nephrotic syndrome strongly prothrombotic. Renal-vein thrombosis is particularly common in membranous nephropathy (up to 30%). Prophylactic anticoagulation is used when serum albumin falls below 2.0-2.5 g/dL.
What is the difference between nephritic and nephrotic syndrome?▾▴
Nephrotic syndrome features heavy proteinuria, low albumin, edema, hyperlipidemia, and a bland urinary sediment. Nephritic syndrome features hematuria, red-cell casts, hypertension, and reduced glomerular filtration from inflammation, with milder proteinuria. They can overlap in some glomerular diseases.
Is foamy urine always nephrotic syndrome?▾▴
No. Persistent foamy urine that does not clear with flushing is suspicious for significant proteinuria and warrants a urine dipstick or protein/creatinine ratio. Transient foam can occur with concentrated urine or fast urine stream. A urine PCR test confirms or excludes nephrotic-range protein loss.
How is membranous nephropathy treated?▾▴
Modern first-line treatment is rituximab 1 g IV ×2 separated by 14 days, repeated at 6 months. KDIGO 2021 supports rituximab in moderate-to-high-risk disease. Alternatives include the modified Ponticelli regimen (cyclophosphamide-steroid) and calcineurin inhibitors. Anti-PLA2R titres are followed to assess response.
What is FSGS?▾▴
Focal segmental glomerulosclerosis is a glomerular disease characterized by scarring in some glomeruli and parts of glomeruli. It causes 20-25% of adult primary nephrotic syndrome. Primary FSGS is a podocytopathy; secondary FSGS arises from hyperfiltration, viral infection, drugs, or genetic podocyte mutations.
How long does treatment for nephrotic syndrome take?▾▴
Pediatric minimal change disease responds within 2-4 weeks of starting steroids; the full course extends 4-6 months with taper. Adult FSGS requires 12-16 weeks of high-dose steroids. Membranous nephropathy responds over 12-24 months. Maintenance therapy and surveillance often continue for years.
Can nephrotic syndrome be cured without steroids?▾▴
Steroids remain first-line in childhood minimal change disease because of high response rates. Alternative agents such as rituximab, calcineurin inhibitors, and mycophenolate are options in steroid-resistant, steroid-dependent, or frequently relapsing cases. Diabetic and viral-related nephrotic syndromes are treated by addressing the underlying cause rather than with steroids.
Does nephrotic syndrome lead to kidney failure?▾▴
Risk depends on cause and treatment response. Pediatric minimal change disease rarely progresses to kidney failure. Adult FSGS progresses in 30-50% over 10 years. Untreated membranous nephropathy progresses in roughly one-third of cases. Achieving complete or partial remission with treatment substantially improves long-term kidney survival.
Can I exercise with nephrotic syndrome?▾▴
Moderate aerobic activity is safe and encouraged once major edema is controlled. Avoid contact sports if anticoagulated due to bleeding risk. Walking, cycling, and swimming are appropriate. Resistance training helps counteract corticosteroid-induced muscle loss in patients on prolonged immunosuppression.
What diet is best for nephrotic syndrome?▾▴
Strict sodium restriction below 2 g per day reduces edema. Protein intake of 0.8-1.0 g/kg/day is appropriate for most patients; very high protein diets can worsen glomerular hyperfiltration. Limit added sugars and saturated fats given hyperlipidemia. Hydration with 1.5-2 L water daily unless restricted.
Should I get vaccinated if I have nephrotic syndrome?▾▴
Yes. Pneumococcal (PCV13 then PPSV23), influenza, hepatitis B, COVID-19, and varicella vaccinations are recommended, ideally before starting major immunosuppression. Live vaccines are generally avoided during active immunosuppression; planning vaccinations with the nephrology team is important.
Can nephrotic syndrome come back after treatment?▾▴
Yes. Pediatric minimal change disease relapses in 60-70% of children within the first year; 30% become frequent relapsers. FSGS, membranous nephropathy, and lupus nephritis all carry relapse risk, particularly when immunosuppression is tapered. Anti-PLA2R titres can predict relapse in membranous nephropathy.
Is nephrotic syndrome hereditary?▾▴
Most cases are not directly inherited. Congenital and infantile nephrotic syndromes have specific genetic causes (NPHS1, NPHS2, LAMB2, WT1). Adult FSGS shows increased risk with APOL1 high-risk variants in Black populations. Genetic testing is offered in early-onset, syndromic, or steroid-resistant disease.
Generalized swelling (anasarca) with abdominal distension, scrotal or labial edema, and pleural effusions producing dyspnea in severe cases.
06Fatigue, malaise, reduced appetite, and easy bruising linked to protein loss, hypoalbuminemia, and altered coagulation.
07Decreased urine output and dark concentrated urine during marked fluid retention; conversely, polyuria from diuretic therapy once started.
08Abdominal pain in children from intestinal-wall edema or, rarely, spontaneous bacterial peritonitis (pneumococcal).
early warning signs
•Persistent foamy urine that does not clear with flushing — easiest at-home indicator of significant proteinuria
•Unexplained ankle swelling lasting beyond a few days in a previously well child or adult
•Periorbital puffiness present on waking in a child with no allergic history
•Unintentional weight gain of more than 2 kg over a week without dietary change
•Detection of 2+ to 4+ protein on a routine dipstick urinalysis
● emergency signs
•Acute shortness of breath with bilateral pleural effusions or pulmonary edema requiring urgent diuresis and oxygen
•Acute unilateral leg swelling with calf tenderness — deep vein thrombosis is markedly increased in nephrotic syndrome (renal-vein thrombosis particularly in membranous nephropathy)
•Sudden severe abdominal pain with fever in a nephrotic child — exclude spontaneous bacterial peritonitis
•Acute kidney injury with oliguria, rising creatinine, and hyperkalemia — may reflect renal-vein thrombosis, severe intravascular depletion, or crescentic transformation
•Severe hypoalbuminemia (<1.5 g/dL) with signs of circulatory collapse — requires urgent inpatient management
04
Anti-PLA2R antibody and anti-THSD7A antibodyDiagnoses primary membranous nephropathy without biopsy in many cases; titres track disease activity and treatment response
05
Hepatitis B surface antigen, hepatitis C antibody, HIV serologyScreens for viral causes of secondary nephrotic syndrome
06
Antinuclear antibody, anti-dsDNA, complement (C3, C4)Identifies lupus nephritis; low C3 and C4 with positive anti-dsDNA supports the diagnosis
07
Serum and urine free light chains, immunofixationExcludes AL amyloidosis and other monoclonal gammopathies in adults over 40
08
Percutaneous kidney biopsyGold standard for histologic diagnosis in adults and steroid-resistant or atypical pediatric cases
Outlook
Outcome depends on histology, age, response to initial therapy, and degree of kidney function at presentation. Pediatric minimal change disease has the best prognosis: 80-90% achieve complete remission with corticosteroids, and even frequent relapsers usually maintain long-term kidney function with appropriate maintenance therapy. Adult minimal change disease responds similarly but with more relapses. Primary FSGS carries a 30-50% risk of progression to end-stage kidney disease over 10 years; partial or complete remission with treatment improves 10-year kidney survival to 80-90% versus 30-50% in unresponsive patients. Primary membranous nephropathy follows a thirds rule: roughly one-third remit spontaneously, one-third have persistent proteinuria with stable kidney function, and one-third progress; modern rituximab-based treatment improves long-term outcomes substantially. Diabetic kidney disease, lupus class V, and amyloidosis follow trajectories of their underlying systemic disease. Across all forms, achieving complete remission (proteinuria <0.3 g/day) is the strongest predictor of long-term kidney preservation, and SGLT2 inhibitors plus RAAS blockade now substantially slow progression even in residual proteinuria.
Viral and drug-related glomerular disease
HIV-associated nephropathy (collapsing FSGS), hepatitis B (membranous nephropathy, membranoproliferative pattern), hepatitis C (membranoproliferative with cryoglobulinemia), NSAIDs (minimal change/membranous), gold, penicillamine, lithium, and bisphosphonates all produce nephrotic syndromes.
risk factors
Age 2-6 years (pediatric)non-modifiable
Peak pediatric incidence is between 2 and 6 years, when minimal change disease is the dominant histology. Boys are affected roughly twice as often as girls in this age band.
Black African ancestrygenetic
Two APOL1 risk alleles increase the risk of FSGS, HIV-associated nephropathy, and hypertensive kidney disease by 10-17×, contributing to the 3-5× higher incidence of FSGS in Black populations in the US and West Africa.
Approximately 50% of SLE patients develop kidney involvement, and 10-20% present with class V (membranous) lupus nephritis manifesting as nephrotic syndrome.
Untreated HIV causes collapsing FSGS in patients with APOL1 risk alleles. Hepatitis B causes membranous nephropathy. Hepatitis C produces membranoproliferative glomerulonephritis with mixed cryoglobulinemia. Antiviral treatment can reverse these.
Obesitymodifiable
Class III obesity (BMI ≥40) increases secondary FSGS risk through hyperfiltration injury. Weight loss reduces proteinuria substantially in obesity-related glomerulopathy.
Solid-organ malignancy in adults over 65non-modifiable
Up to 20% of older adults with membranous nephropathy have an associated solid tumor (lung, breast, colon, prostate). Age-appropriate cancer screening is mandatory at diagnosis.
Prior NSAID, gold, penicillamine, lithium, or bisphosphonate exposuremodifiable
Several drugs produce nephrotic syndrome through podocyte injury (NSAIDs, lithium) or immune-complex membranous patterns (gold, penicillamine). Drug withdrawal typically resolves the proteinuria over weeks to months.
•Lean fish, poultry, and plant proteins over red and processed meat
•Omega-3-rich foods (salmon, sardines, flaxseed, walnuts) for cardiovascular protection
foods to avoid
•Salt-heavy processed foods, canned soups, restaurant meals, and pickles
•Excess animal protein loading that can worsen hyperfiltration in residual CKD
•Sugar-sweetened beverages that complicate metabolic management
•Grapefruit and Seville orange when on tacrolimus or cyclosporine (alters drug levels)
Progression to chronic kidney disease and end-stage kidney disease, particularly in FSGS, membranous nephropathy, and untreated secondary causes.
choosing the right hospital
01On-site percutaneous kidney biopsy capability
02Renal pathology with immunofluorescence and electron microscopy
03Glomerular disease subspecialty clinic
04Hemodialysis and kidney transplantation services
05Pharmacy access to rituximab, calcineurin inhibitors, cyclophosphamide, and IV albumin
Essential facilities
Academic nephrology centers with glomerular disease programsPediatric nephrology servicesTertiary renal pathology laboratoriesTransplant nephrology programsSpecialist outpatient infusion units for rituximab
01Take prescribed immunosuppression at the same time each day; tacrolimus and cyclosporine on an empty stomach with consistent timing for stable levels.
02Check daily weight and report sudden gains.
03Use a urine dipstick at home (where supplied) to track proteinuria trend during remission attempts.
04Keep a symptom diary including edema severity, urine output, and side effects of medication.
05Stay current on all prescribed vaccinations and infection-prevention measures.
06Maintain hydration with 1.5-2 L water daily unless instructed otherwise during severe fluid retention.
Exercise
Moderate aerobic activity (walking, cycling, swimming) of 150 minutes per week is encouraged once major edema is controlled. Avoid contact sports during active heavy proteinuria due to bleeding risk if anticoagulated. Resume normal activity once stable; resistance training is safe and helps offset corticosteroid-induced muscle loss.